Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?

insidermonkey.com · 2026-10-16

Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of their pharmaceutical portfolios.

TickrTrends take: AbbVie currently trades at a valuation that TickrTrends identifies as overvalued within the Healthcare sector, which adds context to comparative analyses between it and competitors like Pfizer. For investors focused on valuation metrics, the current assessment suggests that AbbVie's price may not reflect underlying fundamentals relative to peers in the pharmaceutical industry. A valuation-conscious reader should monitor whether AbbVie's pricing adjusts downward or whether operational performance strengthens enough to justify the current market valuation.

Read the full story at insidermonkey.com →